Profile of Secondary Bone Cancer in Brazzaville

Abstract Full-Text HTML XML Download Download as PDF (Size:162KB) PP. 251-254
DOI: 10.4236/ojra.2013.34039    2,651 Downloads   3,837 Views   Citations


Objectives: To report an epidemiology study and prognosis for metastatic bone tumor. Methodology: It was a descriptive, transversal study on records of patients hospitalized in Rheumatology and Oncology-Radiotherapy departments of the University Teaching Hospital of Brazzaville, Congo from 1 January 2005 to 31 July 2011 (7 years and 6 months). The diagnosis of bone metastasis was made because of the existence of bone pain, or pathological fracture, or bone swelling and a bone-condensing or mixed or osteolytic radiological image. The anatomo-pathological evidence was made after biopsy of the bone lesion or primary cancer. 3687 patients were hospitalized for active cancer, among them 81 had documented bone metastasis. Results: There were 60 men (74.1%) and 21 women (25.9%) with a sex ratio of 2.85. The average age was 53 years, ranging from 3 to 80 years. 75% of patients were more or equal to 50 years old at the discovery of the bone metastasis. Bone pain was the main mode of discovery (67.9% of cases). However, in 6.2% of cases, it was discovered incidentally. The metastasis was bone condensing in 50.7% of cases, osteolytic in 40.7% and mixed in 8.6%. They were unifocal in 25.9% and multifocal in 74.1% of cases. The Primary cancer most frequently found was that of the prostate in 55.6% of cases, breast in 20.7% and rhabdomyosarcoma in 4.9%. In 6.2% of cases, the primary site of cancer was unknown. The average survival was 25 months. Conclusion: The clinical and radiological presentation remains classic. Cancer of the prostate and breast are the main neoplasia responsible for bone metastasis in our series. The discovery of metastasis remains a major evolutionary step of cancer.

Cite this paper

H. Ntsiba, N. N’soundhat, E. Ndounga and A. Ondzala, "Profile of Secondary Bone Cancer in Brazzaville," Open Journal of Rheumatology and Autoimmune Diseases, Vol. 3 No. 4, 2013, pp. 251-254. doi: 10.4236/ojra.2013.34039.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] K. K. Li, E. Sinclair, J. Pope, et al., “A Multidisciplinary Bone Metastases Clinic at Toronto Sunnybrook Regional Cancer Centre. A Review of the Experience from 1999 to 2005,” Journal of Pain Research, Vol. 1, No. 1, 2008, pp. 43-48.
[2] M. S. Virk and J. R. Lieberman, “Tumor Metastasis to Bone,” Arthritis Research and Therapy, Vol. 9, No. S1, 2007, p. 10.
[3] R. Bileckot, R. C. Miakoundoba and J. B. Nkoua Mbon, “Two Brazzaville Series of Bone Metastases,” Carcinol Prat Afrique, Vol. 8, No. 1, 2008, pp. 57-60.
[4] M. Ly, A. Ly, M. Rodrigues, et al., “Cancer in Africa, a New Health Challenge. Examples of Mali and Mali Onco Association,” Bull Cancer, Vol. 97, No. 8, 2010, p. 965.
[5] C. Gombe-Mbalawa and G. Ibara, “Report Functioning Cancer Registry of Brazzaville from January 1st to December 31st 2010,” Cancer Registry of Brazzaville, 2011.
[6] L. Belaksir, N. Seknaji, M. Touimy, S. Janani, et al., “Bone Metastases: Experience of Rheumatology CHU Ibn Rushd at Casa,” Revue Du Rhumatisme, Vol. 77, No. S3, 2010, pp. A131-A325.
[7] N. Seknaji, M. Touimy, L. Belksir, et al., “Contribution of Bone Biopsy in Search of Primary Cancer of Bone Metastases,” Revue Du Rhumatisme, Vol. 77, No. S3, 2010, pp. A131-A325.
[8] M. Vandecandelaere, R. M. Filipo, B. Cortet, L. Catanzariti, B. Duquesnoy and B. Delcambre, “Bone Metastases Revealing: A Comparative Study in 30-Years Intervals,” Revue Du Rhumatisme, Vol. 71, No. 5, 2004, pp. 390-396.
[9] P. Houze, R. Ranaivosoar, A. C. Prost, et al., “Bone Metastases of Prostate Cancer: Contribution of Specific Determination of Bone Alkaline Phosphatase,” Immuno-Analyse & Biologie Specialisee, Vol. 10, 1995, pp. 27-33.
[10] C. Gombe-Mbalawa, D. Diouf, J. B. Nkoua Mbon, et al., “Arrival of Cancer Patients in Advanced Stages: Attempted Identification of Responsibility,” Bull Cancer, Vol. 100, No. 2, 2013, pp. 167-171.
[11] K. Kogahashi, H. Satoh, H. Ishihakawa, et al., “Bone Metastasis Revealing Primary Tumor. Comparison of Two Series Separated by 30 Years,” Joint Bone Spine, Vol. 71, No. 3, 2004, pp. 224-229.
[12] M. H. Vieillard, “Hypercalcemia of Malignancy,” Reflections Rheumatology, Vol. 115, No. 3, 2009, pp. 14-16.
[13] D. Secarecia, “The Cancer-Related Hypercalcemia,” Ca- nadian Family Physician, Vol. 56, No. 1, 2010, pp. 90-92.
[14] H. N. Rakoto-Ratsimba, J. C. Razafinahandry, J. A. B. Razafindrabe, F. R. Raherimandimby and P. Ratokobe, “Paratesticular rhabdomyosarcoma. Case Report,” Medecine Afrique Noire, Vol. 49, No. 2, 2002, pp. 83-86.
[15] S. Nesa, Y. Lefebvre, J. L. Montfort, F. X. Wese and P. Van Cangh, “Paratesticular Rhabdomyosarcoma a Case Report,” Acta Urologica Belgica, Vol. 62, No. 3, 1994, pp. 37-42.
[16] J. Nsonde-Malanda, E. Makosso, J. F. Peko and C. Gombe-Mbalawa, “Bone Metastases of Endometrial Adenocarcinoma. A Case Report with Review of the Literature,” Medecine Afrique Noire, Vol. 54, No. 6, 2007, pp. 313-316.
[17] P. N. Scutellari, G. Addonisio, R. Righi and M. Giganti, “Diagnostic Imaging of Bone Metastasis,” Radiological Medicine, Vol. 100, No. 6, 2000, pp. 429-435.
[18] D. Vilain, A. Hameg and C. Tainturier, “Update on Bone Scintigraphy in Urological Cancers in Adults,” Advances in Urology, Vol. S7, 2008, pp. 202-207.
[19] C. Proust, J. Proust and A. Maubon, “Imaging Bone Metastases. Nuclear Medicine,” Functional and Metabolic Imaging, Vol. 30, No. 3, 2006, pp. 149-154.
[20] L. Belaksir, M. Touimy, S. Janani, et al., “Revealing Bone Metastasis of Prostate Cancer,” Revue Du Rhumatisme, Vol. 77, No. S3, 2010, pp. A131-A325.

comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.